Dr Suzanne Smith
Dr Smith has over 15 years’ experience in the design and development of radiopharmaceuticals for imaging and therapy. She has successfully taken scientific ideas from concept to clinical trials and is the inventor of a number of novel and patented technologies of cyclotron and reactor radiopharmaceuticals. Dr Smith is regularly invited to speak and moderate at conferences and participate in international scientific and organising committees. She is currently applying her scientific knowledge to radioisotope production at the Collider-Accelerator Department of Brookhaven National Laboratory and is an Executive Board Member and Node Director of the ARC Centre of Excellence in Anti-matter Matter Studies.
Prof Dale Bailey
Prof Bailey is Principal Physicist in the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, and Professor in Medical Radiation Sciences at the University of Sydney. He is Co-Director of PharmaScint, a biotech company providing imaging and analytical services to the pharmaceutical industry. Prof Bailey is also the flagship leader for the Neuro-Endocrine tumour (NET) project of Sydney Vital – the Northern Translational Cancer Research Centre. His main area of interest is in the development of quantitative techniques using imaging of in vivo radionuclide tracers in both SPECT (single photon emission computed tomography) and PET (positron emission tomography). Prof Bailey is currently a chief investigator for a number of grants including studying the micro-vascular changes in pulmonary arterial hypertension using ventilation and perfusion SPECT and improving imaging and dosimetry techniques in selective internal radionuclide therapy (SIRT) in liver cancer utilising SIR-Spheres, SPECT and PET.
Dr Paul Donnelly
Dr Donnelly is the group leader of the Donnelly Research Group, University of Melbourne, based in the state-of-art laboratories of the Bio21 Institute of Molecular Science and Biotechnology. Dr Donnelly’s expertise is the application of synthetic inorganic/organic chemistry in biology and materials science, with a particular focus on the application of coordination chemistry to metal-based drugs and the study of metal ions in biological systems. Dr Donnelly has an impressive publication record and is the inventor of a number of novel and patented radiopharmaceutical technologies.